Oda, Yoshinao
Tanaka, Kazuhiro
Hirose, Takanori
Hasegawa, Tadashi
Hiruta, Nobuyuki
Hisaoka, Masanori
Yoshimoto, Masato
Otsuka, Hiroshi
Bekki, Hirofumi
Ishii, Takeaki
Endo, Makoto
Kunisada, Toshiyuki
Hiruma, Toru
Tsuchiya, Hiroyuki
Katagiri, Hirohisa
Matsumoto, Yoshihiro
Kawai, Akira
Nakayama, Robert
Kawashima, Hiroyuki
Takenaka, Satoshi
Emori, Makoto
Watanuki, Munenori
Yoshida, Yukihiro
Okamoto, Takeshi
Mizusawa, Junki
Fukuda, Haruhiko
Ozaki, Toshifumi
Iwamoto, Yukihide
Nojima, Takayuki
Funding for this research was provided by:
National Cancer Center Japan (29-A-3, 2020-J-3, 29-A-3, 2020-J-3, 29-A-3, 2020-J-3, 29-A-3, 2020-J-3, 29-A-3, 2020-J-3, 29-A-3, 2020-J-3, 29-A-3, 2020-J-3, 29-A-3, 2020-J-3, 29-A-3, 2020-J-3, 29-A-3, 2020-J-3, 29-A-3, 2020-J-3, 29-A-3, 2020-J-3, 29-A-3, 2020-J-3, 29-A-3, 2020-J-3, 29-A-3, 2020-J-3, 29-A-3, 2020-J-3, 29-A-3, 2020-J-3, 29-A-3, 2020-J-3, 29-A-3, 2020-J-3, 29-A-3, 2020-J-3, 29-A-3, 2020-J-3, 29-A-3, 2020-J-3, 29-A-3, 2020-J-3, 29-A-3, 2020-J-3, 29-A-3, 2020-J-3, 29-A-3, 2020-J-3, 29-A-3, 2020-J-3)
Japan Society for the Promotion of Science (JP19H03444)
Japan Agency for Medical Research and Development (JP17ck0106336, JP20ck0106614, JP17ck0106336, JP20ck0106614, JP17ck0106336, JP20ck0106614, JP17ck0106336, JP20ck0106614, JP17ck0106336, JP20ck0106614, JP17ck0106336, JP20ck0106614, JP17ck0106336, JP20ck0106614, JP17ck0106336, JP20ck0106614, JP17ck0106336, JP20ck0106614, JP17ck0106336, JP20ck0106614, JP17ck0106336, JP20ck0106614, JP17ck0106336, JP20ck0106614, JP17ck0106336, JP20ck0106614, JP17ck0106336, JP20ck0106614, JP17ck0106336, JP20ck0106614, JP17ck0106336, JP20ck0106614, JP17ck0106336, JP20ck0106614, JP17ck0106336, JP20ck0106614, JP17ck0106336, JP20ck0106614, JP17ck0106336, JP20ck0106614, JP17ck0106336, JP20ck0106614, JP17ck0106336, JP20ck0106614, JP17ck0106336, JP20ck0106614, JP17ck0106336, JP20ck0106614, JP17ck0106336, JP20ck0106614, JP17ck0106336, JP20ck0106614, JP17ck0106336, JP20ck0106614)
Article History
Received: 2 February 2021
Accepted: 12 January 2022
First Online: 21 January 2022
Declarations
:
: Akira Kawai reports personal fees from Takara-Bio, Daiichi Sankyo, Eli Lilly, Eisai, Novartis and Taiho Pharmaceutical outside the submitted work. Makoto Endo reports personal fees from Taisho Pharmaceutical, Daiichi Sankyo, Eli Lilly, Eisai, Novartis, Ayumi Pharmaceutical, and Taiho Pharmaceutical outside the submitted work. Junki Mizusawa reports grants from Ministry of Health, Labour and Welfare, Japan during the conduct of the study; personal fee from Chuugai Pharmaceutical outside the submitted work. Haruhiko Fukuda reports lecture fee from Chuugai Pharmaceutical outside the submitted work. The other authors have nothing to disclose.
: All methods were carried out in accordance with relevant guidelines and regulations. This study (the Japan Clinical Oncology Group study, JCOG0304-A1) protocol was approved by the Protocol Review Committee of the JCOG and by the Institutional Review Boards in each of the 20 participating institutes. Informed consent to participate and publication was obtained from all the patients who were enrolled in the JCOG0304 trial.
: Consent for publication was obtained by all authors prior to submission.
: Akira Kawai reports personal fees from Takara-Bio, Daiichi Sankyo, Eli Lilly, Eisai, Novartis and Taiho Pharmaceutical outside the submitted work. Makoto Endo reports personal fees from Taisho Pharmaceutical, Daiichi Sankyo, Eli Lilly, Eisai, Novartis, Ayumi Pharmaceutical, and Taiho Pharmaceutical outside the submitted work. Junki Mizusawa reports grants from Ministry of Health, Labour and Welfare, Japan during the conduct of the study; personal fee from Chuugai Pharmaceutical outside the submitted work. Haruhiko Fukuda reports lecture fee from Chuugai Pharmaceutical outside the submitted work. The other authors have nothing to disclose.